
|Articles|January 15, 2004
Ruboxistaurin reduces visual loss in diabetic retinopathy
New Orleans-Ruboxistaurin mesylate, a protein kinase C (PKC) beta inhibitor, reduces loss of vision in patients with moderate-ly severe to very severe nonproliferativediabetic retinopathy, researchers reported at the American Diabetes Association meet-ing here.
Advertisement
Newsletter
Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Ophthalmology Times - Clinical Insights for Eye Specialists
1
Ophthalmic innovation by the decades: The 2000s
2
EyePoint Pharmaceuticals details phase 3 program evaluating vorolanib intravitreal insert (DURAVYU) for DME
3
The Residency Report: Social media and the modern ophthalmologist
4
FDA approves Rayner’s RayOne EMV Toric intraocular lens
5